Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01102257 · ClinicalTrials.gov registry record · Phase 2

Dry Eye Assessment and Management: Feasibility Study

A Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Asbell, Penny, M.D..

Completed
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT01102257 is a Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca that has completed, run by Asbell, Penny, M.D.. The registered enrollment target is 23 participants, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01102257, a Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, has completed, sponsored by Asbell, Penny, M.D..

COMPLETED
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statistically relevant data concerning the safety and efficacy of the supplement in patients with dry eye disease.

Interventions

  • DRUG Olive Oil
  • DRUG Omega-3 EFA Supplement

Study Locations (1)

New York

  • Mount Sinai School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2010-01
Est. Completion 2011-03
Phase Phase 2

Sponsor

Asbell, Penny, M.D.

1 total trials

What the Registry Record Tells You About NCT01102257

The ClinicalTrials.gov registry entry for NCT01102257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (94% lower). The listed sponsor is Asbell, Penny, M.D., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Olive Oil is the first listed.

NCT01102257 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01102257 about?

NCT01102257 is a clinical study titled "Dry Eye Assessment and Management: Feasibility Study". The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statist...

What is the current status of trial NCT01102257?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-01. Estimated completion is 2011-03.

What conditions does trial NCT01102257 study?

This clinical trial studies the following conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca.

What interventions are being tested in trial NCT01102257?

The interventions under investigation include: Olive Oil (DRUG), Omega-3 EFA Supplement (DRUG).

Who is sponsoring clinical trial NCT01102257?

This trial is sponsored by Asbell, Penny, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01102257 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.